News

Pathways Neuro Pharma, a pioneering biotech company advancing gene therapies for neurological disorders, is pleased to announce the engagement of Dragonfly 44 Capital (“Dragonfly 44” or “D44 Capital”) as its strategic advisor. Under the terms of this agreement, effective immediately, Dragonfly 44 will provide comprehensive advisory and investment banking services to support Pathways in achieving its strategic goals. This engagement comes at a pivotal moment for Pathways, following key advancements in its proprietary AAV6.2FF gene therapy platform. 

Recently, Pathways addressed important intellectual property matters and strengthened its patent portfolio, further solidifying the company’s position as a leader in the field. Dragonfly 44 will assist Pathways in capital raising and securing strategic partnerships, ensuring the company is well-positioned to accelerate its development pipeline, including its therapies for alcohol use disorder (AUD) and depression. Pathways’ innovative gene therapy approach to treating depression is designed to significantly minimize the side effects commonly associated with current treatments, offering patients a safer and more effective alternative.

Anthony Mack, CEO of Pathways Neuro Pharma, remarked: “The engagement of Dragonfly 44 comes at a time when we have successfully bolstered our patent portfolio, adding further value to our innovative gene therapies. Their expertise will be crucial in helping us secure the resources and partnerships necessary to bring our therapies to patients and meet unmet medical needs in conditions like AUD and depression.” Dragonfly 44 will play a key role in evaluating and pursuing financing and transactional opportunities, including equity, debt, and hybrid capital raises. 

This partnership will enhance Pathways’ financial capabilities as it continues to develop gene therapies targeting central nervous system disorders, with a focus on reducing side effects and improving patient outcomes. About Pathways Neuro Pharma: Pathways Neuro Pharma is committed to developing groundbreaking gene therapies for neurological disorders. Its proprietary AAV6.2FF gene therapy platform, coupled with a robust patent portfolio, positions the company to address critical unmet medical needs in conditions such as AUD and depression, while minimizing side effects.

Warren Lau, General Manager
Pathways Neuro Pharma Inc.
+1 832-758-7488

Pathways Neuro Pharma Inc. is committed to pushing the boundaries of neuroscientific research and addressing unmet medical needs in neurological disorders.

"Dr. Thompson's unparalleled experience, strategic acumen, and proven success in biotechnology will undoubtedly enhance our ability to innovate and advance groundbreaking neurological therapeutics.”— Anthony Mack

Pathways Neuro Pharma Inc., a pioneering biotechnology company specializing in innovative neurological therapeutics, proudly announces the appointment of Dr. Brad Thompson as its Chief Technology Officer. Dr. Thompson, a seasoned biotech professional with an illustrious 39-year career, brings a wealth of expertise in immunotherapy, oncology, infectious disease, autoimmune diseases, and gene therapy.

As the CEO and Founder of Wyvern Pharmaceuticals Inc. and Kickshaw Ventures Ltd. based in Calgary, AB, Dr. Thompson has been at the forefront of biotechnology ventures for nearly four decades. His distinguished career includes 23 years as CEO of two NASDAQ-listed biotech companies and the founding or co-founding of 18 biotech companies, with nine successfully going public and five acquired by other companies.

An influential figure in the life sciences sector, Dr. Thompson's primary areas of interest have been autoimmune disease, oncology, and infectious disease. His extensive experience spans academia, government research, and industry, making him a well-known and respected leader in the field.

Commenting on Dr. Thompson's appointment, Anthony Mack, CEO of Pathways Neuro Pharma Inc., remarked, "We are delighted to welcome Dr. Brad Thompson to our leadership team. His unparalleled experience, strategic acumen, and proven success in biotechnology will undoubtedly enhance our ability to innovate and advance groundbreaking neurological therapeutics."

Dr. Thompson, reflecting on his new role, stated, "Joining Pathways Neuro Pharma Inc. is an exciting opportunity to contribute to the development of transformative solutions in neurological healthcare. I am eager to collaborate with the talented team at Pathways and drive progress in addressing unmet medical needs."

Warren Lau, General Manager
Pathways Neuro Pharma Inc.
+1 832-758-7488

Pathways celebrates its patent issuance as a pioneering achievement in the realm of behavioral healthcare.

"We are proud to contribute to the evolution of neuropharmacology and remain committed to transforming these discoveries into tangible improvements in patient care.”— Anthony Mack

Pathways Neuro Pharma, Inc., a pioneering force in neuropharmacology dedicated to innovative solutions for neurological disorders, is pleased to announce the issuance of a groundbreaking U.S. Patent for its neuroreceptor technology.

The patent, titled "Neuroreceptor Compositions and Methods of Use," received US Patent Number US 11,760,788 on September 19, 2023. This discovery highlights Pathways Neuro Pharma, Inc.'s commitment to novel neuroreceptor compositions and their broad applications. Significantly advancing the development of Pathways' behavioral health pipeline, this marks a notable achievement. This technology has the potential to revolutionize the treatment of disorders such as alcoholism, substance abuse, depression, and associated neurological conditions.

Anthony Mack, CEO of Pathways Neuro Pharma, Inc., remarked, "The patent reflect our team's dedication to advancing neuroscientific research. We are proud to contribute to the evolution of neuropharmacology and remain committed to transforming these discoveries into tangible improvements in patient care."

Pathways is dedicated to advancing the field of neuropharmacology and is committed to developing safe and effective treatments for neurological disorders. This groundbreaking patent is a testament to Pathways’ dedication to innovation and its mission to improve the lives of those affected by neurological disorders. The company looks forward to continuing its research and development efforts and bringing this technology to market in the near future.

Warren Lau, General Manager
Pathways Neuro Pharma Inc.
+1 832-758-7488
warren.lau@pathwaysnp.com

Anthony Mack leads the charge with the Pathways team as they chart new horizons in behavioral health solutions, ushering a new era, in addiction treatment.

"Our combination therapy strategy is designed to bring about a transformative impact, addressing the root causes of addictive behaviors and restoring balance for individuals affected by addiction.”— Anthony Mack

Pathways Neuro Pharma a leading innovator in neuropharmacology, focused on pioneering solutions for neurological disorders proudly announces the appointment of Anthony Mack as its new Chief Executive Officer, signaling a strategic shift towards advancing solutions for addiction treatment. With a wealth of experience in the pharmaceutical industry and strategic business acumen to lead Pathways Neuro Pharma into a new era of innovation.

Pathways Neuro Pharma, known for its commitment to scientific excellence, is refocusing its efforts in the development of proprietary solutions for individuals struggling with addictive behaviors, including alcoholism and opioid addiction.

"Pathways Neuro Pharma is dedicated to transforming the landscape of addiction treatment through innovative science and a comprehensive therapeutic approach," said Anthony Mack. "Our goal is to leverage the latest discoveries in brain processing and mood regulation to unlock the neuro-mechanical basis of addiction."

The company's cutting-edge approach involves the utilization of the latest insights into how the human brain processes consciousness and coordinates mood regulation. Pathways Neuro Pharma is actively engaged in developing a combination therapy approach, incorporating gene therapy to restore and enhance neuro-regulators, alongside pharmaceutical activators to stimulate regulatory function.

"We are entering a critical phase in addiction treatment research, and I am thrilled to lead the efforts at Pathways Neuro Pharma," continued Mr. Mack. "Our combination therapy strategy is designed to bring about a transformative impact, addressing the root causes of addictive behaviors and restoring balance for individuals affected by addiction."

Pathways Neuro Pharma aims to accelerate its addiction-focused research and development initiatives, driving forward a mission to make a meaningful impact on the lives of those grappling with addiction.

Pathways President Doug Centilli enthusiastically welcomed Anthony Mack to the team. Centilli said, "Pathways is poised to achieve great strides in the treatment of addiction. As the company climbs to the next level Tony's experience and leadership will be instrumental in putting Pathways on a fast trak to help alleviate the suffering of so many families afflicted by this terrible disease."

As the new CEO, Anthony Mack will lead a diverse team of researchers, clinicians, and professionals, fostering an environment that encourages innovation and collaboration. Pathways Neuro Pharma remains steadfast in its mission to drive transformative solutions for addiction, utilizing state-of-the-art approaches rooted in neuroscientific discovery.

Warren Lau
Pathways Neuro Pharma Inc.
+1 832-758-7488